GB0425932D0 - Structured phospholipids - Google Patents

Structured phospholipids

Info

Publication number
GB0425932D0
GB0425932D0 GBGB0425932.1A GB0425932A GB0425932D0 GB 0425932 D0 GB0425932 D0 GB 0425932D0 GB 0425932 A GB0425932 A GB 0425932A GB 0425932 D0 GB0425932 D0 GB 0425932D0
Authority
GB
United Kingdom
Prior art keywords
structured phospholipids
phospholipids
structured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0425932.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Priority to GBGB0425932.1A priority Critical patent/GB0425932D0/en
Publication of GB0425932D0 publication Critical patent/GB0425932D0/en
Priority to US11/791,606 priority patent/US20090036410A1/en
Priority to PCT/GB2005/004516 priority patent/WO2006056783A2/en
Priority to EP05808900A priority patent/EP1885377A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
GBGB0425932.1A 2004-11-25 2004-11-25 Structured phospholipids Ceased GB0425932D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB0425932.1A GB0425932D0 (en) 2004-11-25 2004-11-25 Structured phospholipids
US11/791,606 US20090036410A1 (en) 2004-11-25 2005-11-25 Structured Phospholipids
PCT/GB2005/004516 WO2006056783A2 (en) 2004-11-25 2005-11-25 Structured phospholipids for treating autoimmune and neurodegenerative diseases
EP05808900A EP1885377A2 (en) 2004-11-25 2005-11-25 Structured phospholipids for treating autoimmune and neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0425932.1A GB0425932D0 (en) 2004-11-25 2004-11-25 Structured phospholipids

Publications (1)

Publication Number Publication Date
GB0425932D0 true GB0425932D0 (en) 2004-12-29

Family

ID=33561357

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0425932.1A Ceased GB0425932D0 (en) 2004-11-25 2004-11-25 Structured phospholipids

Country Status (4)

Country Link
US (1) US20090036410A1 (en)
EP (1) EP1885377A2 (en)
GB (1) GB0425932D0 (en)
WO (1) WO2006056783A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014001A2 (en) * 2005-07-21 2007-02-01 The Board Of Trustees Of The Leland Stanford Junior University Multiplex determination of lipid specific binding moieties
FR2908658B1 (en) * 2006-11-20 2011-11-11 Centre Nat Rech Scient COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF DISEASES ASSOCIATED WITH OVEREXPRESSION OF TNF AND / OR IL-12
WO2012143860A1 (en) * 2011-04-18 2012-10-26 Jian Guan Ameliorating cognitive decline
US20130281409A1 (en) * 2012-03-19 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Myelin Sheath Fatty Acids that Resolve Neuroinflammation
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077371A (en) * 1937-04-13 Synthetic drx
US2617791A (en) * 1949-09-15 1952-11-11 Trojan Powder Co Recovery of valuable products from pentaerythritol mother liquor
US3082228A (en) * 1959-12-18 1963-03-19 Escambia Chem Corp Method for producing monoesters of polyunsaturated fatty acids
US3158541A (en) * 1959-12-18 1964-11-24 Escambia Chem Corp Product for reduction of blood cholesterol concentration
FR2003425A1 (en) * 1968-03-07 1969-11-07 Unilever Nv EDIBLE PLASTIC FAT COMPOSITIONS AND PROCESS FOR PREPARING THEM
US3671563A (en) * 1968-04-19 1972-06-20 Smith Kline French Lab Glycerol 3-(2,2,2-trichloroethyl) carbonate
US3558656A (en) * 1968-04-19 1971-01-26 Smith Kline French Lab Glycerol trichloroethyl carbonate and derivatives
US3676472A (en) * 1969-07-28 1972-07-11 American Home Prod Certain linoleic and linolenic acid ester fractions of vegetable oils and derivatives thereof
US3748348A (en) * 1970-07-27 1973-07-24 Lever Brothers Ltd Directed-interesterified glyceridic oils having a high linoleic acid content and process for their production
US3671557A (en) * 1970-09-17 1972-06-20 Smith Kline French Lab 1,2-diacylglycerol 3-(2,2,2-trichloroethyl) carbonates
GB1370021A (en) * 1971-03-25 1974-10-09 Unilever Ltd Process for preparing usaturated carboxylic acids
US3972907A (en) * 1975-03-24 1976-08-03 G. D. Searle & Co. Anti-hyperlipidemic fatty acids and esters
US4048202A (en) * 1975-04-11 1977-09-13 G. D. Searle & Co. 3-O-Alkanoylglyceric acids
US4181670A (en) * 1978-12-11 1980-01-01 G. D. Searle & Co. Phenyl 5Z,8Z,11Z,14Z-eicosatetraenoate and congeners
EP0092076B1 (en) * 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Lipid composition for oral, enteral or parenteral feeding
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
US4701468A (en) * 1983-04-15 1987-10-20 Roussel-Uclaf Oxidized triglycerides having therapeutic utility
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
GB8404463D0 (en) * 1984-02-21 1984-03-28 Efamol Ltd Microbiological production of essential fatty acids
AT383130B (en) * 1984-05-15 1987-05-25 Chemie Linz Ag METHOD FOR THE PRODUCTION OF PHOSPHATIDYLCHOLINES AND PHOSPHATIDYLETHANOLAMINES SUBSTITUTED DIFFERENTLY AT C1 AND C2 OVER THE NEW COMPOUNDS 1-0-TRITYLGLYCEROPHOSPHOCHOLIN OR RELATED (1-0, N-DITYHOHOLINE)
GB2178752B (en) * 1985-07-12 1989-10-11 Unilever Plc Substitute milk fat
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5151291A (en) * 1985-12-27 1992-09-29 Nisshin Flour Milling Co., Ltd. Glycerides of eicosapentaenoic acid, processes for preparing the same and oil and fat products containing the same
US5306730A (en) * 1986-02-03 1994-04-26 Kabushiki Kaisha Yakult Honsha Botulinum toxin neutralizer
US5227403A (en) * 1986-10-01 1993-07-13 The Nisshin Oil Mills, Ltd. Fats and oils having superior digestibility and absorptivity
US4867965A (en) * 1986-10-02 1989-09-19 Revlon, Inc. Fatty acid diesters
US4832975A (en) * 1987-09-29 1989-05-23 The Procter & Gamble Company Tailored triglycerides having improved autoignition characteristics
US5008126A (en) * 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
IT1247165B (en) * 1991-03-15 1994-12-12 Fidia Spa THERAPEUTIC USE OF PHOSPHATIDYLSERINE AND DERIVATIVES IN DEGENERATIVE PATHOLOGIES, ALSO ASSOCIATED WITH IMMUNITARY DYSFUNCTIONS.
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
ES2136189T3 (en) * 1993-01-15 1999-11-16 Abbott Lab STRUCTURED LIPIDS.
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JPH06279311A (en) * 1993-03-26 1994-10-04 Sagami Chem Res Center Activation agent for protein kinase c isozyme
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5663450A (en) * 1993-08-17 1997-09-02 Cv Therapeutics Macrophage lipid chemoattractant
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
JPH07309773A (en) * 1994-05-16 1995-11-28 Sagami Chem Res Center Acetylcholine release promoter
FR2722410B1 (en) * 1994-07-15 1996-10-04 Grinda Jean Robert PROCESS FOR THE STABILIZATION OF POLYUNSATURATED FATTY ACIDS AND THE USE OF THESE STABILIZED ENTHERAPEUTIC PRODUCTS
US6410078B1 (en) * 1995-04-28 2002-06-25 Loders-Croklaan B.V. Triglycerides, rich in polyunsaturated fatty acids
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
US6015798A (en) * 1995-10-10 2000-01-18 Colgate Palmolive Company Method for reducing the damaging effects of radiation therapy on animal skin and mucosa
GB2328155B (en) * 1996-04-12 2000-08-02 Peptide Technology Pty Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US5753702A (en) * 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
CA2259330C (en) * 1996-06-29 2003-03-18 The Scottish Agricultural College Improvement of male fertility with antioxidants and/or polyunsaturated fatty acids
GB9617847D0 (en) * 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
KR100657642B1 (en) * 1996-10-11 2006-12-19 스카리스타 리미티드 Oil comprising eicosapentaenoic acid and/or stearidonic acid
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
SK112399A3 (en) * 1997-02-21 2000-12-11 Abbott Lab Methods and compositions for reducing the incidence of necrotizing enterocolitis
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6432684B1 (en) * 1997-04-11 2002-08-13 Abbott Laboratories Human desaturase gene and uses thereof
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US6051754A (en) * 1997-04-11 2000-04-18 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US7101914B2 (en) * 1998-05-04 2006-09-05 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6696584B2 (en) * 1998-05-04 2004-02-24 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6214372B1 (en) * 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
CN1219064C (en) * 1998-08-04 2005-09-14 嘉吉有限公司 Plant fatty acid desaturase promoters
KR100325581B1 (en) * 1998-08-07 2002-08-24 오우택 Analgesic compositions containing substances that result from lipoxygenase metabolism of arachidonic acid
AU5561999A (en) * 1998-08-13 2000-03-06 Wistar Institute, The Methods for reducing atherosclerotic plaques
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
EG22407A (en) * 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
DE60106026T2 (en) * 2000-06-23 2006-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-ARACHIDONYLGLYCEROL (2-AG) - AN INHIBITOR OF TUMOR NECROSIS FACTOR ALFA AND NEUROPROTEKTOR OF BRAIN IN CLOSED HEAD BREAKDOWNS
JP2002047176A (en) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd Ige production suppressing agent
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2815227B1 (en) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES
NO310176B1 (en) * 2000-11-13 2001-06-05 Wadlund As Composition for skin containing chitosan-conjugated CLA and chitosan-conjugated vitamin A or a <beta> -cyclodextrin-conjugated vitamin A and method of preparation and use thereof
US6528040B1 (en) * 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
US20030032674A1 (en) * 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
US6582040B2 (en) * 2001-09-28 2003-06-24 Hewlett-Packard Company Method of ejecting fluid from an ejection device
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
US6677470B2 (en) * 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
AUPS082102A0 (en) * 2002-03-01 2002-03-21 Women's And Children's Hospital Therapeutic properties of oils
MXPA04008711A (en) * 2002-03-08 2004-12-13 Monsanto Technology Llc Treatment and prevention of inflammatory disorders.
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
US7335481B2 (en) * 2002-07-24 2008-02-26 Christer Owman Methods of identifying compounds that affect a fatty acid cell-surface receptor
US7074418B2 (en) * 2002-11-18 2006-07-11 Changaris David G Conjugated fatty acid based emulsion and methods for preparing and using same
US6841573B2 (en) * 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US20040209953A1 (en) * 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation

Also Published As

Publication number Publication date
WO2006056783A3 (en) 2007-03-01
US20090036410A1 (en) 2009-02-05
EP1885377A2 (en) 2008-02-13
WO2006056783A2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
DE602005025924D1 (en) Royl-coa-desaturase
DE602005020252D1 (en) Röhrenförmige prothese
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
DE602005010905D1 (en) Roboterhandvorrichtung
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
DE602005011286D1 (en) Pyrazolopyridinderivate
DE502005007040D1 (en) Laryngoskop
DE602004014986D1 (en) Terminal-box
DE502005007456D1 (en) Nanoemulsionen
EG23651A (en) Culturama
DE602005008719D1 (en) Notinformationsschild
HK1182716A1 (en) Oxidized phospholipids
DE602005026795D1 (en) Polythiourethan
DE602005010119D1 (en) Roboterhandvorrichtung
DE602005010440D1 (en) Lymerdispersionen
DE602005025096D1 (en) Rotationsdämpfer
DE502005009795D1 (en) Modulares gelenkprothesensystem
DE602005003029D1 (en) Polyaminoamidmonoepoxyaddukte
DE502004004685D1 (en) Giessmaschine
DE502005010653D1 (en) Eiten
GB0425932D0 (en) Structured phospholipids
DE502005006813D1 (en) Common-rail-injektor
DE502004004917D1 (en) Multiaxialkomplex
DE502005004945D1 (en) Auto-splice-system
GB0403616D0 (en) Derivatised phospholipids

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)